Cardio Diagnostics opened higher at $1.97, compared with its previous close of $1.92. In the last trading session, the stock traded between $1.80 and $1.99. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Cardio Diagnostics is now worth
$ 1.66
Resulting in a loss of
$ 98.34 (98.34%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.02 (-1.04%)
Day High
$1.99
Day Low
$1.80
Day Open
$1.97
Prev Close
$1.92
Volume
24,478
1W Return
14.46%
1M Return
6.20%
3M Return
1.60%
6M Return
2.70%
1Y Return
-50.13%
Fundamentals
Market Cap ($ Mn)
6
PE Ratio
-
PB Ratio
0.73
PEG Ratio
-
ROE
-70.96%
ROCE
-68.54%
EPS (TTM)
$-0.51
Investment Returns
1 Week
14.46%
1 Month
6.20%
3 Months
1.60%
6 Months
2.70%
9 Months
43.94%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
26Aug
Cardio Diagnostics report highlights rural cardiovascular care gap and access challenges
Cardio Diagnostics releases updated rural health report focusing on cardiovascular care gaps. 46% of U.S. counties lack a practicing cardiologist, exacerbating access issues. Rural areas have 39.8 physicians per 100,000 residents versus 53.3 in urban areas. 28% of rural Americans lack broadband, hindering telehealth adoption. Report proposes model including upskilling clinicians and epigenetic testing.
Cardio Diagnostics (NASDAQ: CDIO) launched its in-house CLIA-certified lab in Iowa City, replacing third-party processing. The move targets ~40% gross margins at scale and aims to reduce the current 7–10 day turnaround time. The facility also supports research into epigenetic biomarkers for cardiovascular health.
2mo ago
5Aug
Cardio Diagnostics to host investor call on August 20
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) will host an investor call on August 20, 2026, at 3 p.m. Central Time. The session will cover updates on its Epi+Gen CHD™ and PrecisionCHD™ tests, clinical studies, reimbursement progress, and growth strategies. Investors can join via webcast or phone using passcode 4543643#. The company leverages AI-driven genetic-epigenetic technology for cardiovascular disease detection.
3mo ago
24Jun
Atlas Healthcare Physicians to cover Cardio Diagnostics tests
Atlas Healthcare Physicians (AHP) will cover Cardio Diagnostics Holdings, Inc.'s Epi+Gen CHD and PrecisionCHD tests for its members starting May 2026. The tests assess coronary heart disease risk and aid diagnosis through simple blood tests requiring no radiation or fasting. This partnership aims to improve cardiovascular outcomes and expand access to precision medicine across AHP's network in Southern California.
